Tivic Health Systems Inc. Common Stock Q3 2025 Earnings Recap

Tivic Health Systems demonstrated significant progress in its strategic transformation, advancing its biologic pharmaceutical pipeline and making strides in its lead candidate, entolimod, despite some manufacturing delays.

Key Takeaways

• Successfully licensed entolimod, expanding the portfolio into biologic pharmaceuticals with a focus on immune system therapies.
• Initiated the transfer of INDs for entolimod, enabling swift potential entry into Phase II clinical studies for multiple indications, including acute radiation syndrome.
• Verified production of entolimod proteins, marking a key milestone in advancing towards CGMP compliance for regulatory submissions.
• Completed a VNS optimization study revealing surprising capabilities, suggesting potential reassessment of commercial strategies.
• Active engagement with BARDA and military stakeholders to explore entolimod's application as a countermeasure for ARS and potential stockpiling.